In a post earlier this week, we looked at two of Warren Buffett's positions in transportation stocks. He has also revealed in SEC filings that Berkshire Hathaway (NYSE: BRK.A) has bought 1.51 million ADRs of GlaxoSmithKline (NYSE: GSK).
Vivian Lewis, who holds GSK in her Global Investing portfolio, explains, "GlaxoSmithKline is off 22% since our purchase late in 2006, so how nice that the Oracle of Omaha sprung for it now. Why did he?
1) The stock has a a 4.5% yield, always nice. Buffett is a value player, not a growth man, especially in the current economy. Drugs are refuges in a downturn;
2) A recently defused scandal over its lead drug, diabetes treatment Avandia, whose nasty side-effects (heart trouble) surprised doctors and researchers. The heart trouble also affects competing diabetes drugs, result of too-rigorous attempts to 'normalize' blood sugar levels. There will be lawsuits but they ignore the fact that the side-effect was unanticipated;
3) The firm has a full pipeline of drugs, mostly bought by deals with small research shops which is how GSK is spending its R&D money;
4) The company has seen aggressive cost cutting by its multinational management (something national champion drug companies cannot do). Post-merger, GSK is leaner and meaner. The firm is Anglo-American and the retiring CEO is French.
5) The firm has a strong vaccine division, a growth area now. GSK is close to getting FDA approval for an infant rotavirus shot, without the tummy side-effects of a competing vaccine from Wyeth."
Each day, Steven Halpern's TheStockAdvisors.com offers the latest market commentary and favorite investment ideas from the nation's leading financial newsletter advisors.
Retailers can't wait for Black Friday, open Thursday
Tiffany's serves up solid quarterly earnings
Cramer on BloggingStocks: This bullish retail story looks like a good fit 
Reader Comments (Page 1 of 1)
4-10-2008 @ 5:16PM
Babui said...
Here's another theory on why Buffett bought GSK. It is the best-in-class among the Drugs&Biotech companies http://seekingalpha.com/article/71789-why-did-buffett-buy-glaxo-smithkline-and-kraft